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Summary
Background Sub-Saharan Africa and south Asia contributed 81% of 5·9 million under-5 deaths and 77% of 2·6 million 
stillbirths worldwide in 2015. Vital registration and verbal autopsy data are mainstays for the estimation of leading 
causes of death, but both are non-specific and focus on a single underlying cause. We aimed to provide granular data 
on the contributory causes of death in stillborn fetuses and in deceased neonates and children younger than 5 years, 
to inform child mortality prevention efforts.
Methods The Child Health and Mortality Prevention Surveillance (CHAMPS) Network was established at sites in 
seven countries (Baliakandi, Bangladesh; Harar and Kersa, Ethiopia; Siaya and Kisumu, Kenya; Bamako, Mali; 
Manhiça, Mozambique; Bombali, Sierra Leone; and Soweto, South Africa) to collect standardised, population-based, 
longitudinal data on under-5 mortality and stillbirths in sub-Saharan Africa and south Asia, to improve the accuracy 
of determining causes of death. Here, we analysed data obtained in the first 2 years after the implementation of 
CHAMPS at the first five operational sites, during which surveillance and post-mortem diagnostics, including 
minimally invasive tissue sampling (MITS), were used. Data were abstracted from all available clinical records of 
deceased children, and relevant maternal health records were also extracted for stillbirths and neonatal deaths, to 
incorporate reported pregnancy or delivery complications. Expert panels followed standardised procedures to 
characterise causal chains leading to death, including underlying, intermediate (comorbid or antecedent causes), and 
immediate causes of death for stillbirths, neonatal deaths, and child (age 1–59 months) deaths.
Findings Between Dec 10, 2016, and Dec 31, 2018, MITS procedures were implemented at five sites in Mozambique, 
South Africa, Kenya, Mali, and Bangladesh. We screened 2385 death notifications for inclusion eligibility, following 
which 1295 families were approached for consent; consent was provided for MITS by 963 (74%) of 1295 eligible cases 
approached. At least one cause of death was identified in 912 (98%) of 933 cases (180 stillbirths, 449 neonatal deaths, 
and 304 child deaths); two or more conditions were identified in the causal chain for 585 (63%) of 933 cases. The most 
common underlying causes of stillbirth were perinatal asphyxia or hypoxia (130 [72%] of 180 stillbirths) and congenital 
infection or sepsis (27 [15%]). The most common underlying causes of neonatal death were preterm birth 
complications (187 [42%] of 449 neonatal deaths), perinatal asphyxia or hypoxia (98 [22%]), and neonatal sepsis 
(50 [11%]). The most common underlying causes of child deaths were congenital birth defects (39 [13%] of 304 deaths), 
lower respiratory infection (37 [12%]), and HIV (35 [12%]). In 503 (54%) of 933 cases, at least one contributory 
pathogen was identified. Cytomegalovirus, Escherichia coli, group B Streptococcus, and other infections contributed to 
30 (17%) of 180 stillbirths. Among neonatal deaths with underlying prematurity, 60% were precipitated by other 
infectious causes. Of the 275 child deaths with infectious causes, the most common contributory pathogens were 
Klebsiella pneumoniae (86 [31%]), Streptococcus pneumoniae (54 [20%]), HIV (40 [15%]), and cytomegalovirus (34 [12%]), 
and multiple infections were common. Lower respiratory tract infection contributed to 174 (57%) of 304 child deaths.
Interpretation Cause of death determination using MITS enabled detailed characterisation of contributing conditions. 
Global estimates of child mortality aetiologies, which are currently based on a single syndromic cause for each death, 
will be strengthened by findings from CHAMPS. This approach adds specificity and provides a more complete 
overview of the chain of events leading to death, highlighting multiple potential interventions to prevent under-5 
mortality and stillbirths.
Funding Bill & Melinda Gates Foundation.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Sub-Saharan Africa and south Asia contributed 81% of 
5·9 million under-5 deaths1 and 77% of 2·6 million 
stillbirths worldwide in 2015.2 Although mortality 
among children aged younger than 5 years has declined 
globally in the past two decades,3 considerable 
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geographical differences exist. Child mortality remains 
disproportionately high in sub-Saharan Africa and 
south Asia.1 Understanding the aetiologies of child 
mortality is hindered by a high proportion of child 
deaths at the community level, inadequate access to 
medical services, scarcity of pre-mortem and post-
mortem diagnostic tools, coexisting illnesses (which are 
difficult to distinguish using available tools), absence of 
functional vital registration systems, and insufficient 
validity and precision of common methods for cause of 
death determination.4–9 The paucity of credible, reliable 
mortality data limits national capa bilities to optimally 
prioritise scarce resources for reducing mortality.10
Minimally invasive tissue sampling (MITS), also 
known as minimally invasive autopsy, was developed to 
improve the accurate ascertainment of causes of death in 
resource-constrained settings.11 Compared with complete 
diagnostic autopsy, MITS is less physically disruptive, 
faster and potentially more socioculturally acceptable,12 
and less resource-intensive.13 MITS has been validated 
against complete diagnostic autopsies in perinatal and 
paediatric deaths with International Classification of 
Diseases, tenth revision (ICD-10) diagnostic categories 
coinciding in 68–89% of cases (complete diagnostic 
autopsies vs MITS diagnoses).14,15
The Child Health and Mortality Prevention Surveillance 
(CHAMPS) Network was established to collect stan-
dardised, population-based, longitudinal data within a 
network of sites in areas with high child mortality, with 
the overarching objectives of understanding and tracking 
preventable causes of childhood death and stillbirths 
globally.16 In this study, we analysed data obtained in the 
first 2 years after the implementation of CHAMPS to 
characterise the types of results that will contribute to 
burden of disease estimates, future policy making, 
advocacy, and research agendas, as data accumulate over 
time. We aimed to provide data from the first 2 years of 
CHAMPS activities on all under-5 deaths and stillbirths, 
Research in context
Evidence before this study
In low-income and middle-income countries (LMICs), data used 
for estimating cause of death distributions for populations are 
primarily based on verbal autopsy interviews and, occasionally, 
death certificates using hospital-based clinical data, both of 
which have limited accuracy. There is poor concordance 
between findings from verbal autopsy or death certificates and 
the diagnoses obtained from complete diagnostic autopsy, 
which is considered the gold standard for cause of death 
investigation. Complete diagnostic autopsies, however, pose 
challenges in many settings, including limited cultural and 
religious acceptability, because they might be considered 
disfiguring and time consuming and can substantially delay 
burial. Furthermore, in many LMICs, qualified personnel and 
other resources required for the procedure are scarce. 
Considering that the majority of global child mortality occurs in 
LMICs, an acceptable and feasible approach that would inform 
reliably on causes and the chain of events leading to death in a 
selection of high mortality areas would generate more robust 
and credible data, thus providing the basis for more accurate 
and specific estimates of childhood mortality.
Added value of this study
The Child Health and Mortality Prevention and Surveillance 
Network includes sites in sub-Saharan Africa and south Asia, 
with the joint goal of generating and accumulating more 
precise, detailed, and robust data on causes of child mortality 
in locations across these regions with high child mortality. 
Deaths were investigated using a variety of methodologies, 
including minimally invasive tissue sampling (MITS), a post-
mortem approach using biopsy needles for sampling key 
organs and body fluids, which has been validated as an 
acceptable proxy method to complete diagnostic autopsy for 
cause of death ascertainment. Molecular testing, classical 
microbiology, histopathology, and immunohistochemistry 
were used to assess samples obtained from MITS. Additionally, 
we used verbal autopsy and collected antemortem clinical 
data. In-country panels of experts analysed each death using all 
available data and determined the most plausible sequence 
and causes of death. In this study, we demonstrate the 
contribution of these methods for detailing cause of death 
data at a level of granularity previously unavailable in LMICs 
and show the high acceptance rate for the MITS procedure in a 
range of LMIC settings. We describe the first insights regarding 
the advantages of this approach for under-5 mortality 
surveillance, which could highlight potential pathways to 
prevent child mortality.
Implications of all the available evidence
The mortality surveillance approach described in this study has 
the potential to increase the precision and credibility of cause of 
death estimates. Rather than focusing on a singular underlying, 
often non-specific, cause of death, which might not fully 
inform interventions to reduce mortality, we have presented 
detailed descriptions of the underlying and immediate causes 
of death, which together with any antecedent conditions, 
comprise the chain of events leading to death. This information 
provides an improved understanding of conditions associated 
with death in regions with high child mortality. MITS with 
associated laboratory analysis facilitates the identification of 
specific microorganisms and thus provides a clearer 
understanding of the contribution of pathogens to the 
histopathological changes observed in each case and to overall 
child mortality. MITS data might also provide a foundation for 
the calibration and refinement of the interpretation of data 
from existing tools (especially verbal autopsy and death 
certificates) for future use in global burden of disease estimates 
and to better inform public health policy.
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using MITS to obtain detailed, high quality and pathogen-
specific cause of death data.
Methods
Mortality and demographic surveillance
The CHAMPS Network included sites in seven countries: 
Baliakandi, Bangladesh; Harar and Kersa, Ethiopia; 
Siaya and Kisumu, Kenya; Bamako, Mali; Manhiça, 
Mozambique; Bombali, Sierra Leone; and Soweto, South 
Africa. Site characteristics and selection criteria have 
been described previously.17 As of Dec 31, 2018, five sites 
had implemented minimally invasive tissue sampling, 
and data from these sites are included in this report. 
Some sites used pre-existing Health and Demographic 
Surveillance System (HDSS) catchment areas.18–21 New 
surveillance areas were developed for CHAMPS within 
informal settlements in Kisumu, Baliakandi, and Soweto. 
The total population size for catchment areas within each 
country (with the exception of South Africa) ranged 
between 170 000 and 227 219 indi viduals.21 The Soweto 
site, in the absence of an established HDSS, used the 
entire township and surrounding informal settlement 
areas (population of approximately 1·3 million people) as 
the catchment area during the majority of the reported 
period while the HDSS was being established. Sites built 
relationships with com munities22 and health facilities 
within catchment areas, posting CHAMPS staff at 
health facilities and developing networks of community 
reporters to receive notifications of under-5 deaths and 
stillbirths within the first 24 h.17 At most sites, death 
notifications were initially mostly received from primary 
referral health facilities, subse-quently expanding to 
notifications of deaths occurring outside health facilities.
After receiving notifications of deaths or stillbirths, 
CHAMPS staff approached families rapidly for eligibility 
screening. Eligible cases were aged younger than 
60 months, and they or their parents resided within the 
study catchment area. MITS eligibility required that 
CHAMPS staff were notified within 36 h of death (or ≤72 h 
if post-mortem refrigeration used) and that the body of the 
stillborn fetus or deceased child was available for analysis. 
Families provided consent for the MITS procedure, verbal 
autopsy, and clinical data abstraction, and we present data 
on these MITS-eligible fetuses, neonates, or children in 
this report. Stillborn fetuses and deceased neonates and 
infants who were not eligible for the MITS procedure (eg, 
CHAMPS received a notification more than 36 h after 
their death or consent for MITS was not given) were asked 
to consent for only verbal autopsy interview and clinical 
data abstraction, and will be reported elsewhere.17
Parents or guardians of stillborn fetuses or deceased 
children provided written informed consent before 
collection of data, specimens, or information on the 
mothers. Ethics committees overseeing investigators at 
each site and at Emory University (Atlanta, GA, USA) 
approved overall and site-specific protocols, as appro-
priate. The Centers for Disease Control and Prevention 
(CDC; Atlanta, GA, USA) relied on the Emory University 
committee to review the overall protocol and on 
appropriate ethical review committees at the sites where 
CDC staff were directly engaged. Protocols have been 
published previously.
Specimen and data collection
Trained CHAMPS staff took photographs to identify 
dysmorphic features and took anthropometric measure-
ments before specimen collection. In sterile conditions, 
tissue specimens were collected using biopsy needles 
from the lungs, heart, brain, liver, and bone marrow.23 
They also collected peripheral blood, cerebrospinal fluid, 
stool, and nasopharyngeal secretions. Site laboratories 
tested post-mortem blood samples for HIV DNA or 
RNA by PCR, malaria thick and thin smears, and rapid 
diagnostic tests; blood and cerebrospinal fluid were 
cultured. Five custom TaqMan Array Cards (ThermoFisher 
Scientific, Waltham, MA, USA) with specific molecular 
assays were used to detect 116 pathogen targets from lung 
tissue, blood, cerebro spinal fluid, rectal brush (collecting 
stool), and naso pharyngeal swabs.23,24 Pathology labora-
tories at each site and at the CDC applied histopathology 
to all tissues, including routine stains. Special stains, 
such as tissue Gram stain, targeting microorganisms 
and immunohistochemistry were done when relevant, at 
pathology labora tories at the CDC.25 Data were abstracted 
from all available clinical records of deceased children 
and relevant maternal health records were abstracted for 
stillbirths, neonatal deaths, and others with reported 
pregnancy or delivery complications. Trained interviewers 
used appropriate-language trans lations of the 2016 WHO 
verbal autopsy instrument17,26 to interview caregivers of 
enrolled deceased children within 4 weeks of death, when 
feasible.
Cause of death determination
All data available for each case were reviewed by 
Determination of Cause of Death (DeCoDe) panels 
convened at each site, which consisted of paediatricians, 
obstetricians, other health-care providers, epidemiologists, 
pathologists, and microbiologists.27 The panels reviewed 
available case data and determined the chain of events 
leading to death using WHO ICD-10 and WHO application 
of ICD-10 to deaths during the perinatal period (ICD-PM) 
guidelines.28,29 For cases in which more than one condition 
led to death, the process included documenting the entire 
causal chain leading to death, as in a standard death 
certificate, including underlying cause, intermediate 
(referred to on the WHO standard death certificate as 
comorbid or antecedent causes), and immediate cause. To 
be included in the causal chain, the panels considered 
whether appropriate management or prevention of that 
condition could have prevented the death. Additionally, the 
panels identified any other contributing causes of death 
and the main maternal factors contributing to perinatal 
deaths. The immediate cause of death was the most 
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proximal cause leading to death, and antecedent or 
comorbid causes were others contributing directly to the 
chain of events leading to death. The underlying cause was 
the disease or injury that initiated the chain of events that 
led to the death. Each case could have one immediate 
cause and multiple comorbid or antecedent causes 
identified, which could be in the same general category 
(eg, lower respiratory tract infection could be listed twice in 
the same causal chain if, for example, a viral pneumonia 
led to a bacterial superinfection). Additionally, the panels 
considered all available data for evidence of signs of life 
(such as postnatal respiration, heartbeat, or movement); 
the presence of any resulted in a case being categorised as 
a neonatal death rather than a stillbirth. The DeCoDe 
process was standardised across the network using 
diagnosis standards for defining and coding common 
childhood causes of death and organi sation of specific and 
homogeneous training at all sites.27 Causes were grouped 
into standardised categories for analysis (appendix p 2). All 
analyses were conducted using R (version 3.6.3).
Role of the funding source
The funder of the study provided input on study design 
and site selection and suggested edits on the final 
versions of the manuscript, but had no role in data 
collection, data analysis, or data interpretation. The 
corresponding author had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
Between Dec 10, 2016, and Dec 31, 2018, MITS procedures 
were implemented at five sites (in Bangladesh, Kenya, 
Mali, Mozambique, and South Africa); 2385 case 
notifications of stillborn or deceased children were 
screened and determined to be eligible for data collection 
(figure). Surveillance staff were notified within 36 h of 
death for 1749 (73%) of 2385 eligible stillborn fetuses or 
deceased children, of which 1605 (92%) notifications 
were received within 24 h (appendix p 15). Eligible deaths 
that occurred in health facilities were more likely to be 
notified within 24 h than deaths occurring outside of 
health facilities (1360 [74%] of 1755 deaths in health 
facilities vs 233 [43%] of 536 deaths outside of health 
facilities). Median time from death to notification was 
13·0 h (IQR 2·0–47·5).
Of 2385 cases eligible for inclusion in CHAMPS, 
1430 were eligible for MITS. Of the 1430 eligible cases, 
the families of 1295 (91%) cases were approached for 
MITS consent, of whom 963 (74%) families consented 
to MITS (189 [80%] among 236 stillbirths, 468 [71%] 
among 662 neonates, and 306 [77%] among 397 children 
aged 1–59 months; figure). Of all 963 cases for whom 
we received parental consent for inclusion, MITS was 
completed in 933 cases (180 still births, 449 neonatal 
deaths, 304 children’s deaths). MITS was not done in 
30 cases after we received familial consent because the 
body of the fetus or child was no longer available after 
consent (n=17); pathologists were not available for the 
procedure (n=5); the specimen collection kit was not 
available (n=3); consent was withdrawn (n=3); or the body 
of the child or fetus was not in sufficient condition to 
test (n=2). MITS was completed within 24 h of death for 
616 (66%) of 933 cases (appendix p 15); in two cases, MITS 
was done more than 72 h after death. Surveillance was 
initiated on different dates at each of the five sites during 
the study period; all sites started by primarily including 
deaths that had occurred at health facilities. Overall, 
832 (89%) of 933 deaths occurred at health facilities. 
464 (50%) of 933 cases were from the Soweto site (which 
had a disproportionately larger catchment area in 2017 
and began collecting MITS earlier than three other sites), 
in which the main medical facility is a large hospital with 
a large neonatal intensive care unit (table 1). DeCoDe 
panel assessments of the 933 cases formed the basis for 
this descriptive analysis. Overall, among the 933 cases, at 
least one cause of death was identified in 912 (98%) of 
cases, and in 585 (63%) of cases, we identified two or 
more conditions in the causal chain (appendix p 17). 
In 503 (54%) of 933 of cases, at least one contributory 
pathogen was identified.
A specific cause leading to fetal death was identified 
in 172 (96%) of 180 stillbirths (appendix p 17). Of 
180 stillbirths, perinatal asphyxia or hypoxia was the 
most frequently identified underlying cause of death 
(130 [72%] cases), with congenital infection or sepsis the 
second most common underlying cause (27 [15%] cases; 
table 2). A pathogen was determined to have contributed 
to the causal chain leading to stillbirth in 30 (17%) of 
180 cases (data not shown). The most common 
Figure: Case selection process for CHAMPS
CHAMPS=Child Health and Mortality Prevention Surveillance. MITS=minimally invasive tissue sampling. 
DeCoDe=Determination of Cause of Death. *Does not include known cases outside of catchment areas, not 
available for eligibility screening, or considered lost to follow-up. †Cases that were approached for MITS, non-MITS, 
or MITS followed by non-MITS consent and refused. ‡Cases that were considered MITS eligible, but were not 
approached for either MITS or non-MITS consent.
2385 cases eligible for CHAMPS*
1149 families consented 
to non-MITS
30 MITS not possible 
963 families consented 
to MITS
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contributory pathogens were cytomegalo virus (n=7), 
Escherichia coli or Shigella (n=6), Streptococcus agalactiae 
(n=6), and Enterococcus faecalis (n=5; table 3). An 
illustrative stillbirth case is presented in the appendix 
(p 19). Among 172 stillbirths for which a cause was 
determined, a maternal or obstetric factor was identified 
in 154 (90%) of cases. Using ICD-PM classifications,28 
the most common maternal factors were complications 
of placenta, cord, and mem branes (66 [43%] of 154 cases) 
and maternal medical and surgical conditions (54 [35%] 
of 154 cases), predominantly associated with hypertensive 
disorders, such as pre-eclampsia and eclampsia (table 4; 
appendix p 18).
At least one cause of death was identified for 442 (98%) 
of 449 neonatal deaths, with more than one condition 
determined to be in the causal chain leading to death in 
330 (73%) of 449 neonatal deaths (appendix p 17). Of the 
449 neonatal deaths, the most common underlying cause 
categories were preterm birth complications (187 [42%]), 
perinatal asphyxia or hypoxia (98 [22%]), neonatal sepsis 
(50 [11%]), congenital birth defects (39 [9%]), and congenital 
infection (20 [4%]; table 2). The most frequent comorbid or 
antecedent causes and immediate causes included preterm 
birth complications (182 [41%]), neonatal sepsis (126 [28%]), 
lower respiratory tract infections (86 [19%]), and meningitis 
or encephalitis (61 [14%]; table 2).
Overall, 240 (53%) of 449 neonatal deaths involved at 
least one infectious condition in the causal chain: 
224 (93%) of 240 deaths involved at least one contributory 
pathogen, and 151 (34%) of 449 deaths involved more than 
one pathogen (data not shown). Of the 240 neonatal 
deaths with at least one infectious condition in the causal 
chain, the most common contributory pathogens were 
Acinetobacter baumannii (97 [40%] of cases with an 
infectious condition), Klebsiella pneumoniae (74 [31%]), and 
E coli (27 [11%]; table 3). Among 88 neonates whose death 
was attributed to an infectious cause and who were 
admitted to hospital less than 48 h before death, the most 
common pathogens identified were K pneumoniae (n=19), 
E coli (n=17), and S agalactiae (n=14; data not shown). 
The most common conditions associated with pathogens 
were lower respiratory tract infections and sepsis (table 3). 
Of the 227 neonatal deaths involving preterm birth 














Stillbirth 41 (9%) 48 (33%) 39 (21%) 31 (33%) 21 (46%) 180 (19%)
Death in the first 24 h 81 (17%) 35 (24%) 20 (11%) 15 (16%) 11 (24%) 162 (17%)
Early neonate (1 to 6 days) 122 (26%) 16 (11%) 20 (11%) 17 (18%) 10 (22%) 185 (20%)
Late neonate (7 to 27 days) 74 (16%) 5 (3%) 12 (7%) 8 (8%) 3 (7%) 102 (11%)
Infant (28 days to <12 months) 98 (21%) 15 (10%) 48 (26%) 13 (14%) 0 174 (19%)
Child (12 months to less than 60 months) 48 (10%) 27 (18%) 43 (24%) 11 (12%) 1 (2%) 130 (14%)
Religion of primary caregiver
Muslim 1 (<1%) 1 (1%) 0 95 (100%) 38 (83%) 135 (14%)
Christian 303 (65%) 82 (56%) 172 (95%) 0 0 557 (60%)
African traditional religion 3 (1%) 32 (22%) 10 (5%) 0 0 45 (5%)
Other or no religion 157 (34%) 31 (21%) 0 0 8 (17%) 196 (21%)
Sex of deceased fetus, neonate, or child
Female 186 (40%) 62 (42%) 91 (50%) 50 (53%) 18 (39%) 407 (44%)
Male 277 (60%) 84 (58%) 90 (49%) 45 (47%) 28 (61%) 524 (56%)
Unknown 1 (<1%) 0 1 (1%) 0 0 2 (<1%)
Time from death to notification, h
≤24 360 (78%) 146 (100%) 166 (91%) 95 (100%) 46 (100%) 813 (87%)
>24 104 (22%) 0 16 (9%) 0 0 120 (13%)
Time from death to MITS procedure, h
≤24 238 (51%) 133 (91%) 104 (57%) 95 (100%) 46 (100%) 616 (66%)
>24 225 (48%) 13 (9%) 78 (43%) 0 0 316 (34%)
Unknown 1 (<1%) 0 0 0 0 1 (0%)
Location and timing of death
Facility (≤24 h after admission) 127 (27%) 53 (36%) 49 (27%) 23 (24%) 16 (35%) 268 (29%)
Facility (>24 h after admission) 318 (69%) 84 (58%) 89 (49%) 51 (54%) 30 (65%) 572 (61%)
Community 19 (4%) 9 (6%) 44 (24%) 21 (22%) 0 (0%) 93 (10%)
Data are n (%). CHAMPS=Child Health and Mortality Prevention Surveillance. MITS=minimally invasive tissue sampling.
Table 1: Characteristics of cases with complete cause of death determination, by CHAMPS Network site
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infectious condition that contributed to their death (data 
not shown). A neonatal death that demonstrates the 
identification of the causative organism for a death due 
to pneumonia and sepsis in a premature neonate is 
presented in the appendix (p 19).
Of 304 child deaths, at least one cause of death was 
identified in 298 (98%) cases, and more than one cause 
of death was identified in 230 (76%) cases (appendix 
p 17). The most common underlying causes of death 
were congenital birth defects (39 [13%] of 304 cases), 
lower respiratory tract infection (37 [12%]), HIV 
(35 [12%]), malnutrition (31 [10%]), and preterm birth 
complications (29 [10%]; table 2). The most common 
causes of death across all causes (underlying cause, 
comorbid or antecedent causes, and immediate cause) 
were lower respiratory tract infections (174 [57%] of 
304 cases) and sepsis (123 [40%]; table 2). Lower 
respiratory tract infections contributed to 59% of deaths 
resulting from malnutrition and to 62% of those resulting 
from congenital abnormalities (data not shown).
Overall, 275 (90%) of 304 child deaths had at least one 
infectious condition listed in the causal chain, among 
which at least one contributory pathogen was identified in 
249 (91%) of 275 cases, and 196 (64%) of 304 cases involved 
more than one contributory pathogen. The most common 
contributory pathogens were K pneumoniae (86 [31%] of 
275 deaths with infectious causes), S pneumoniae 
(54 [20%]), HIV (40 [15%]), and cytomegalovirus (34 [12%]; 
table 3). Among the 165 children with an infectious cause 
of death who were hospitalised for less than 48 h before 
death, the most common pathogens identified were 
S pneumoniae (45 [27%]), K pneumoniae (28 [17%]), and 
Plasmodium falciparum (25 [15%]; data not shown). 
Pathogens were most commonly associated with sepsis 
and lower respiratory tract infections (at any position in 
the causal chain; table 3), which were collectively 
associated with 73% of child deaths. The detailed cause-of-
death information available for an infant with multiple 
contributing causes of death, including a congenital 
condition and at least one pathogen contributing to death, 
is shown in the appendix (p 19).
Discussion
Pathology-based surveillance for child mortality in 
regions with the highest child mortality is beginning to 
identify the causes of stillbirths and neonatal and child-
hood deaths with unprecedented detail. We implemented 
real-time child mortality surveillance systems that 
identified and notified us of deaths among stillbirths and 
children aged younger than 5 years across five CHAMPS 
network sites in sub-Saharan Africa and Bangladesh. 
Around three-quarters of families who were approached 
consented to the MITS procedure, showing that MITS is 
feasible and can be readily accepted in high-mortality 
settings where complete diagnostic autopsies might not 
be feasible. These findings represent an early assessment 
and will evolve over time.
These data provide detailed causes of child mortality 
and stillbirths, yielding insights for the development of 












Perinatal asphyxia or hypoxia 5 (3%) 130 (72%) 135 (75%)
Congenital infection or sepsis 7 (4%) 27 (15%) 30 (17%)
Congenital birth defects 2 (1%) 7 (4%) 8 (4%)
Other neonatal disorders 6 (3%) 2 (1%) 8 (4%)
Neonatal preterm birth complications 4 (2%) 1 (1%) 5 (3%)
Umbilical cord complications 1 (1%) 1 (1%) 2 (1%)
Placental complications 0 2 (1%) 2 (1%)
Syphilis 0 2 (1%) 2 (1%)
Birth trauma 1 (1%) 0 1 (1%)
Malpresentation before labour 1 (1%) 0 1 (1%)
Neonatal deaths (n=449)
Preterm birth complications 182 (41%) 187 (42%) 227 (51%)
Sepsis 134 (30%) 50 (11%) 181 (40%)
Perinatal asphyxia or hypoxia 29 (6%) 98 (22%) 127 (28%)
Lower respiratory tract infections 86 (19%) 4 (1%) 90 (20%)
Meningitis or encephalitis 61 (14%) 4 (1%) 65 (14%)
Other neonatal disorders 52 (12%) 9 (2%) 60 (13%)
Congenital birth defects 13 (3%) 39 (9%) 47 (10%)
Congenital infection 27 (6%) 20 (4%) 46 (10%)
Neonatal encephalopathy 34 (8%) 7 (2%) 41 (9%)
Neonatal aspiration syndromes 10 (2%) 5 (1%) 15 (3%)
Other respiratory disease 9 (2%) 0 9 (2%)
Kidney disease 8 (2%) 0 8 (2%)
Other infections 7 (2%) 1 (<1%) 8 (2%)
Other 4 (1%) 1 (<1%) 5 (1%)
Liver disease 3 (1%) 0 3 (1%)
Chorioamnionitis and membrane complications 0 3 (1%) 3 (1%)
Birth trauma 2 (<1%) 0 2 (<1%)
Paralytic ileus and intestinal obstruction 2 (<1%) 0 2 (<1%)
Other disorders of fluid, electrolyte, and acid-base 
balance
1 (<1%) 1 (<1%) 2 (<1%)
Placental complications 1 (<1%) 1 (<1%) 2 (<1%)
Umbilical cord complications 1 (<1%) 1 (<1%) 2 (<1%)
HIV 0 2 (<1%) 2 (<1%)
Syphilis 0 2 (<1%) 2 (<1%)
Liver disease 1 (<1%) 0 1 (<1%)
Maternal HIV 1 (<1%) 0 1 (<1%)
Other endocrine, metabolic, blood, and immune 
disorders
1 (<1%) 0 1 (<1%)
Caesarean delivery 0 1 (<1%) 1 (<1%)
Diarrheal diseases 0 1 (<1%) 1 (<1%)
Injury 0 1 (<1%) 1 (<1%)
Maternal hypertension 0 1 (<1%) 1 (<1%)
Maternal infection 0 1 (<1%) 1 (<1%)
Measles 0 1 (<1%) 1 (<1%)
Obstructed labour and fetal malpresentation 0 1 (<1%) 1 (<1%)
(Table 2 continues on next page)
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high under-5 mortality rates. We observed that at least 
one pathogen contributed to 17% of stillbirths in this 
analysis. Similarly, lower respiratory tract infection was 
identified in the causal chain of 57% of deaths in children 
aged 1–59 months. By contrast, if only the underlying 
cause was considered, lower respiratory tract infection 
would have accounted for only 12% of child deaths. 
Preterm birth complications were common among 
neonatal deaths; however, infectious diseases contributed 
to mortality in 62% of those preterm births, providing 
multiple possible targets for life-saving interventions. 
Current burden of disease estimates would likely 
underestimate multiple contrib utors, many of which 
could be important targets for intervention. Such 
findings offer a new perspective on strategic child 
mortality prevention by highlighting pathways, such as 
lower respiratory tract infection and sepsis, which are 
common across many underlying cause categories and 
are potential targets for prevention.
The use of histopathology and immunohistochemistry 
in CHAMPS provides the capacity to distinguish infection 
with an inflammatory response from post-mortem 
artifacts. Post-mortem contamination by gastrointestinal 
and other normal flora is a key concern when interpreting 
MITS data. The eligibility criteria for MITS required 
that we were notified of deaths within 36 h (or ≤72 h 
if refrigerated) to limit the amount of tissue autolysis 
and potential post-mortem overgrowth.30 Additionally, the 
DeCoDe panels considered all data available for each case 
to define causes of death and did not include detected 
pathogens in the causal chain if other evidence did not 
provide conclusive support. For example, K pneumoniae 
was identified in the causal chain, associated with 
pneumonia, sepsis, and meningitis for a substantial num-
ber of deaths; however simply detecting K pneumoniae did 
not translate to determining that it caused the death. One 
of the key early findings from CHAMPS might be the 
importance of nosocomial and community-acquired 
K pneumoniae-associated morality. Although some studies 
have suggested the importance of K pneumoniae in child 
mortality,31,32 this pathogen has not previously been 
considered to be a key contributory causal pathogen for 
child mortality; if consistent over time, CHAMPS data are 
likely to drive the development of new tools and strategies 
to target this pathogen to prevent child mortality.
Because of the potential for inherent variability for 
interpretation of data and diagnoses assigned by DeCoDe 
panels, we developed and applied standardised diagnostic 
criteria,27 coordinated standard operating procedures 
across sites and reviewed 10% of cases from each site by 
all of the panels, and adhered to ICD-10 and ICD-PM 
standards in assigning underlying cause and causal 
chain.
Cause of death determination in CHAMPS has some 
important limitations. Most of the initial cases included 
in this analysis of data obtained during the first 2 years of 











(Continued from previous page)
Child deaths* (n=304)
Lower respiratory tract infections 143 (47%) 37 (12%) 174 (57%)
Sepsis 119 (39%) 6 (2%) 124 (41%)
Malnutrition 18 (6%) 31 (10%) 49 (16%)
Congenital birth defects 13 (4%) 39 (13%) 45 (15%)
Diarrhoeal diseases 19 (6%) 24 (8%) 43 (14%)
HIV 0 35 (12%) 35 (12%)
Preterm birth complications 15 (5%) 29 (10%) 32 (11%)
Malaria 7 (2%) 24 (8%) 31 (10%)
Meningitis or encephalitis 28 (9%) 2 (1%) 30 (10%)
Other infections 21 (7%) 6 (2%) 27 (9%)
Injury 2 (1%) 15 (5%) 17 (6%)
Other respiratory disease 12 (4%) 5 (2%) 16 (5%)
Other 8 (3%) 2 (1%) 10 (3%)
Other neurological disorders 7 (2%) 4 (1%) 10 (3%)
Liver disease 5 (2%) 3 (1%) 8 (3%)
Other endocrine, metabolic, blood, and immune 
disorders
6 (2%) 2 (1%) 7 (2%)
Congenital infection 2 (1%) 4 (1%) 6 (2%)
Anaemias 5 (2%) 0 5 (2%)
Poisoning 4 (1%) 1 (<1%) 5 (2%)
Heart diseases 3 (1%) 2 (1%) 5 (2%)
Tuberculosis 3 (1%) 2 (1%) 5 (2%)
Kidney disease 4 (1%) 0 4 (1%)
Other neonatal disorders 4 (1%) 0 4 (1%)
Paralytic ileus and intestinal obstruction 3 (1%) 2 (1%) 4 (1%)
Other skin and subcutaneous diseases 2 (1%) 2 (1%) 4 (1%)
Sickle cell disorders 1 (<1%) 3 (1%) 4 (1%)
Other disorders of fluid, electrolyte, and acid-base 
balance
3 (1%) 0 3 (1%)
Other immunodeficiencies 2 (1%) 1 (<1%) 3 (1%)
Epilepsy 1 (<1%) 2 (1%) 3 (1%)
Cancer 0 3 (1%) 3 (1%)
Maternal HIV 0 3 (1%) 3 (1%)
Neonatal encephalopathy 1 (<1%) 1 (<1%) 2 (1%)
Other injury 1 (<1%) 1 (<1%) 2 (1%)
Upper respiratory tract infections 1 (<1%) 1 (<1%) 2 (1%)
Measles 0 2 (1%) 2 (1%)
Liver disease 1 (<1%) 0 1 (<1%)
Other gastrointestinal disease 1 (<1%) 0 1 (<1%)
Motor neuron disease 0 1 (<1%) 1 (<1%)
Perinatal asphyxia or hypoxia 0 1 (<1%) 1 (<1%)
Road injuries 0 1 (<1%) 1 (<1%)
Sudden infant death syndrome 0 1 (<1%) 1 (<1%)
Data are n (%). Specific ICD-10 codes comprising each cause of death category are shown in the appendix (p 2). Cases 
with undetermined and unclassified causes were excluded from this table (eight stillbirths, seven neonatal deaths, and 
six child deaths). Counts in the immediate, comorbid, or underlying cause column do not always equal the sum of 
counts in the immediate or comorbid cause columns, since an individual case could have one or more diagnoses in a 
given category in both immediate or comorbid cause columns, but was counted as a single case in the immediate, 
comorbid, or underlying cause column. *Age 1–59 months.
Table 2: All identified cause of death categories, by age group and position in causal chain
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the findings presented in this study might not fully 
reflect the underlying populations from which cases 
arose. More than half of cases in this study originated 
from a single large tertiary hospital in Soweto, where the 
neonatal unit has had ongoing nosocomial gram-negative 
bacterial transmission (predominately Acinetobacter),33 
and distribution of causes of death and care available for 
this population are likely to differ from that at the other 
sites. In April, 2018, the catchment area for CHAMPS in 
Soweto was reduced from the entire township to a nested 
HDSS population similar in size to other CHAMPS 
sites. With the accumulation of cases from other sites, 
from cases hospitalised less than 48 h thereby repre-
senting community acquired infections and increasingly 
from community settings in the future, the distribution 
of total cases across CHAMPS sites will become more 
geographically balanced and reflective of areas with 
high under-5 mortality in sub-Saharan Africa and south 
Asia. Cause-specific mortality fractions and pathogen 
prevalence derived from CHAMPS data should not yet be 
interpreted as statistically valid estimates beyond these 
sites.
Post-mortem studies can provide valuable data that 
were not otherwise available at the time of death, time 
of physician certification, or verbal autopsy. However, 
current CHAMPS testing and interview procedures do not 
systematically evaluate some potentially important causes, 
such as congenital heart disease, intracranial bleeding, 
some types of poisonings or toxic exposures, certain 
inborn errors of metabolism, genetic disorders without 
characteristic physical features, or sociocultural factors 































Cytomegalovirus 6 0 1 0 0 0 7 7 4%
E coli or Shigella 4 0 6 0 0 0 10 6 3%
S agalactiae 2 1 4 0 0 0 7 6 3%
E faecalis 2 0 4 0 0 0 6 5 3%
Streptococcus 3 0 2 0 0 0 5 5 3%
S pneumoniae 1 0 2 0 0 0 3 2 1%
Treponema pallidum 2 0 0 0 0 0 2 2 1%
Coagulase-negative 
staphylococcus
0 0 1 0 0 0 1 1 1%
Enterobacter 0 0 1 0 0 0 1 1 1%
Enterobacter cloacae 1 0 v 0 0 0 1 1 1%
H influenzae type B 0 0 1 0 0 0 1 1 1%
Klebsiella oxytoca 1 0 1 0 0 0 2 1 1%
K pneumoniae 0 0 1 0 0 0 1 1 1%
P aeruginosa 1 0 0 0 0 0 1 1 1%
Sneathia amnionii 1 0 0 0 0 0 1 1 1%
Neonatal deaths (n=449)
A baumannii 0 27 77 50 1 0 155 97 22%
K pneumoniae 0 21 61 35 0 0 117 74 16%
E coli or Shigella 0 12 20 7 0 0 39 27 6%
S agalactiae 0 10 19 3 0 0 32 24 5%
S aureus 0 2 10 7 0 0 19 16 4%
Streptococcus 0 5 2 6 0 0 13 12 3%
E faecalis 0 2 6 1 0 0 9 9 2%
Candida albicans 0 4 4 0 2 0 10 7 2%
S pneumoniae 0 2 3 3 0 0 8 7 2%
Candida glabrata 0 3 4 0 1 0 8 6 1%
Cytomegalovirus 0 6 0 0 1 0 7 6 1%
Listeria monocytogenes 0 7 0 0 0 0 7 6 1%
Enterococcus faecium 0 0 5 0 0 0 5 5 1%
Candida parapsilosis 0 3 1 0 0 0 4 4 1%
Candida 0 2 1 0 0 0 3 3 1%
(Table 3 continues on next page)
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of these conditions would differ depending on site 
resources. CHAMPS is investigating several methods to 
improve diagnostic accuracy for such causes of death. For 
example, CHAMPS diagnosis of prematurity was often 
based on documented birthweight when data on last 
maternal menstrual period were unavailable, which could 
misclassify babies who were small for gestational age; 
thus, assessment of methods to better estimate gesta-
tional age (including biomarkers) is planned. Other 
diagnostic methods under consider ation include improved 
detection of maternal pre-eclampsia or eclamp sia in the 
fetus or placenta and systematic screening for common 
environmental toxins and poisoning. For cases with 
localised lesions, the sensitivity of MITS for detecting 
infectious or other conditions might be less than 100%;14 
however, the practice of collecting multiple specimens 
from each target organ decreases the likelihood that a 
diffuse process leading to death would be missed.
Post-mortem tissue sampling was accepted by many 
families in a wide variety of settings and resulted in high-
resolution cause of death data. The use of MITS, combined 
with other data, and comprehensive assessment by expert 
panels provided greater detail on causes of death than 






























(Continued from previous page)
Child deaths* (n=304)
K pneumoniae 0 11 55 54 0 0 120 86 28%
S pneumoniae 0 7 22 46 0 0 75 54 18%
HIV 0 38 0 3 0 0 41 40 13%
Cytomegalovirus 4 12 4 24 0 0 44 34 11%
Plasmodium falciparum 0 0 0 0 0 27 27 30 10%
A baumannii 0 4 24 10 0 0 38 29 10%
S aureus 0 2 12 22 0 0 36 28 9%
H influenzae 0 1 5 19 0 0 25 20 7%
E coli 0 9 9 4 0 0 22 19 6%
Respiratory syncytial virus 0 1 0 17 0 0 18 18 6%
Adenovirus 0 5 2 11 0 0 18 16 5%
Pneumocystis jirovecii 0 1 1 17 0 0 19 16 5%
P aeruginosa 0 3 9 9 0 0 21 15 5%
Streptococcus 0 1 2 9 0 0 12 10 3%
Parainfluenza virus type 3 0 1 0 9 0 0 10 9 3%
The 15 most frequently identified pathogens for each age group are presented. The total number of conditions in the columns might exceed the total number of cases for each 
age group because cases could have more than one condition contributing to death. Cases with no pathogens identified in the causal chain were excluded from this table. 
E coli=Escherichia coli. S agalactiae=Streptococcus agalactiae. E faecalis=Enterococcus faecalis. S pneumoniae=Streptococcus pneumoniae. H influenzae=Haemophilus influenzae. 
K pneumoniae=Klebsiella pneumoniae. P aeruginosa=Pseudomonas aeruginosa. A baumannii=Acinetobacter baumannii. S aureus=Staphylococcus aureus. *Age 1–59 months.
Table 3: Number of times pathogens were identified in causal chain leading to death, by condition and age group 
Maternal factor 1: 
complications of 
placenta, cord, and 
membranes













Congenital malformations, deformations and 
chromosomal abnormalities 
1 (1%) 0 1 (1%) 1 (1%) 3 (2%)
Birth trauma 0 0 0 0 0
Perinatal asphyxia or hypoxia 50 (32%) 10 (6%) 20 (13%) 44 (29%) 124 (81%)
Infection 15 (10%) 1 (1%) 0 9 (6%) 25 (16%)
Other specified antepartum or intrapartum disorder 0 0 1 (1%) 0 1 (1%)
Disorders related to fetal growth 0 1 (0·6%) 0 0 1 (1%)
Total 66 (43%) 12 (8%) 22 (14%) 54 (35%) 154 (100%)
Data are n (%). ICD-PM maternal condition groups listed in the appendix (p 18).
Table 4: Stillbirth cause by maternal factor
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registration. Over time, epidemiological and clinical 
insights are anticipated that would be unattainable with 
currently used methods. A single underlying cause of 
death is not sufficient to characterise precipitating, 
potentially preventable factors associated with mortality in 
settings where child mortality is high. The surveillance 
described in this study used a combination of novel and 
highly precise approaches, which provides the potential 
for new evidence that can be used to reduce 
preventable childhood mortality.
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